
    
      The goal of this study is to determine if the administration of glecaprevir and pibrentasvir
      (G/P) for 4 weeks beginning in the immediate peri-transplant period prevents establishment of
      HCV infection in HCV negative recipients receiving transplanted kidneys from HCV RNA positive
      donors.
    
  